Class of 2022
Scientific Areas of Expertise: Drug Discovery and Development, Molecularly Targeted Therapeutics, Precision Medicine
For unparalleled contributions to establishing personalized, anticancer therapeutics including his co-development of imatinib, the first tyrosine kinase inhibitor effective for the treatment of chronic myelogenous leukemia and beneficial when administered to patients with gastrointestinal stromal tumors or small cell lung cancer, research which has since provided the foundation for the development of numerous molecular targeted therapeutics.